Connect with us
[ad_1] Biogen’s Alzheimer’s Drug Could be Expensive Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s...
[ad_1] Biogen’s Alzheimer’s Drug Could be Expensive Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s...